Hyperlipidemia as a Risk Factor for Cardiovascular Disease

Robert H. Nelson

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. Current classification schemes and treatment levels for hyperlipidemia are based on the National Cholesterol Education Panel's Adult Treatment Program-3 (ATP-III) guidelines. Extensive research over the past decade has raised the question whether or not ATP-III guidelines are sufficiently aggressive. New guidelines from ATP-IV are expected to be released in the near future, but in the meantime physicians are faced with uncertainty about how low to target low-density lipoprotein cholesterol, whether to pharmacologically treat high-density lipoprotein cholesterol and triglyceride levels, and how best to achieve target goals.

Original languageEnglish (US)
Pages (from-to)195-211
Number of pages17
JournalPrimary Care - Clinics in Office Practice
Volume40
Issue number1
DOIs
StatePublished - Mar 2013

Fingerprint

Hyperlipidemias
Cardiovascular Diseases
Adenosine Triphosphate
Guidelines
LDL Cholesterol
HDL Cholesterol
Uncertainty
Cholesterol
Physicians
Lipids
Education
Therapeutics
Research

Keywords

  • Cardiometabolic risk
  • CVD risk factors
  • Dyslipidemia
  • Hypercholesterolemia
  • Hypertriglyceridemia

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Hyperlipidemia as a Risk Factor for Cardiovascular Disease. / Nelson, Robert H.

In: Primary Care - Clinics in Office Practice, Vol. 40, No. 1, 03.2013, p. 195-211.

Research output: Contribution to journalArticle

@article{864372b5cad04c3a9da2984a94ebaa5f,
title = "Hyperlipidemia as a Risk Factor for Cardiovascular Disease",
abstract = "Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. Current classification schemes and treatment levels for hyperlipidemia are based on the National Cholesterol Education Panel's Adult Treatment Program-3 (ATP-III) guidelines. Extensive research over the past decade has raised the question whether or not ATP-III guidelines are sufficiently aggressive. New guidelines from ATP-IV are expected to be released in the near future, but in the meantime physicians are faced with uncertainty about how low to target low-density lipoprotein cholesterol, whether to pharmacologically treat high-density lipoprotein cholesterol and triglyceride levels, and how best to achieve target goals.",
keywords = "Cardiometabolic risk, CVD risk factors, Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",
author = "Nelson, {Robert H.}",
year = "2013",
month = "3",
doi = "10.1016/j.pop.2012.11.003",
language = "English (US)",
volume = "40",
pages = "195--211",
journal = "Primary Care - Clinics in Office Practice",
issn = "0095-4543",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Hyperlipidemia as a Risk Factor for Cardiovascular Disease

AU - Nelson, Robert H.

PY - 2013/3

Y1 - 2013/3

N2 - Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. Current classification schemes and treatment levels for hyperlipidemia are based on the National Cholesterol Education Panel's Adult Treatment Program-3 (ATP-III) guidelines. Extensive research over the past decade has raised the question whether or not ATP-III guidelines are sufficiently aggressive. New guidelines from ATP-IV are expected to be released in the near future, but in the meantime physicians are faced with uncertainty about how low to target low-density lipoprotein cholesterol, whether to pharmacologically treat high-density lipoprotein cholesterol and triglyceride levels, and how best to achieve target goals.

AB - Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. Current classification schemes and treatment levels for hyperlipidemia are based on the National Cholesterol Education Panel's Adult Treatment Program-3 (ATP-III) guidelines. Extensive research over the past decade has raised the question whether or not ATP-III guidelines are sufficiently aggressive. New guidelines from ATP-IV are expected to be released in the near future, but in the meantime physicians are faced with uncertainty about how low to target low-density lipoprotein cholesterol, whether to pharmacologically treat high-density lipoprotein cholesterol and triglyceride levels, and how best to achieve target goals.

KW - Cardiometabolic risk

KW - CVD risk factors

KW - Dyslipidemia

KW - Hypercholesterolemia

KW - Hypertriglyceridemia

UR - http://www.scopus.com/inward/record.url?scp=84873586706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873586706&partnerID=8YFLogxK

U2 - 10.1016/j.pop.2012.11.003

DO - 10.1016/j.pop.2012.11.003

M3 - Article

C2 - 23402469

AN - SCOPUS:84873586706

VL - 40

SP - 195

EP - 211

JO - Primary Care - Clinics in Office Practice

JF - Primary Care - Clinics in Office Practice

SN - 0095-4543

IS - 1

ER -